GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ensysce Biosciences Inc (NAS:ENSC) » Definitions » Price-to-Owner-Earnings

Ensysce Biosciences (Ensysce Biosciences) Price-to-Owner-Earnings : (As of Jun. 13, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Ensysce Biosciences Price-to-Owner-Earnings?

As of today (2024-06-13), Ensysce Biosciences's share price is $0.545. Ensysce Biosciences does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Ensysce Biosciences's Price-to-Owner-Earnings or its related term are showing as below:


ENSC's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 34.435
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-13), Ensysce Biosciences's share price is $0.545. Ensysce Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-3.77. Therefore, Ensysce Biosciences's PE Ratio for today is At Loss.

As of today (2024-06-13), Ensysce Biosciences's share price is $0.545. Ensysce Biosciences's EPS without NRI for the trailing twelve months (TTM) ended in was $-3.77. Therefore, Ensysce Biosciences's PE Ratio without NRI for today is At Loss.


Ensysce Biosciences Price-to-Owner-Earnings Historical Data

The historical data trend for Ensysce Biosciences's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ensysce Biosciences Price-to-Owner-Earnings Chart

Ensysce Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
- - - -

Ensysce Biosciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ensysce Biosciences's Price-to-Owner-Earnings

For the Biotechnology subindustry, Ensysce Biosciences's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ensysce Biosciences's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ensysce Biosciences's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Ensysce Biosciences's Price-to-Owner-Earnings falls into.



Ensysce Biosciences Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Ensysce Biosciences's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.545/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ensysce Biosciences  (NAS:ENSC) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Ensysce Biosciences Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Ensysce Biosciences's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Ensysce Biosciences (Ensysce Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
7946 Ivanhoe Avenue, Suite 201, La Jolla, CA, USA, 92037
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the?Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform.
Executives
Bob G Gower director 402 TIMBERWILDE LANE, HOUSTON TX 77024
Lynn Kirkpatrick director, officer: Chief Executive Officer 110 110TH AVENUE NE, SUITE 685, BELLEVUE WA 98004
Nilab Osman officer: Chief Medical Officer C/O ENSYSCE BIOSCIENCES, INC., 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Lee M. Rauch director C/O ENSYSCE BIOSCIENCES, INC., 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Linda Pestano officer: Chief Development Officer 7946 IVANHOE AVENUE, LA JOLLA CA 92037
Kevin Geoffrey Birkett officer: Chief Commercial Officer 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
William K Schmidt officer: Chief Medical Officer TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
David Carl Humphrey officer: Chief Financial Officer 4767 NEXUS CENTRE DR, SAN DIEGO CA 92121
William H Chang director, 10 percent owner C/O SEMLER SCIENTIFIC, INC., 911 BERN COURT, SUITE 110, SAN JOSE CA 95112
Andrew Benton director 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Adam Levin director 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Jeffrey Millard officer: Chief Operating Officer 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Richard Chester Wright officer: Chief Business Officer 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Steven Robert Martin director 11011 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Curtis Rosebraugh director 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037